Navigation Links
New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia

ation of SEROQUEL was administered twice-daily and escalated from 50 mg/day to 400 mg/day over a five-day period. The most common adverse events seen in the active treatment groups during the trial were somnolence and dizziness. The incidences of adverse events leading to discontinuation were low: 5.3%, 2.7%, and 2.5% in the SEROQUEL XR 400, 600, 800 mg/day groups; 4.9% in the immediate release SEROQUEL group; and 2.5% in the placebo group. Individual extrapyramidal symptoms (EPS)-related adverse events occurred in three patients or less in all treatment groups.(1,2)

    (+) Schizophrenic symptomatology measured on 30-item Positive and Negative

        Syndrome Scale (PANSS) scale. Each symptom was rated on a severity

        scale from 1-7. PANSS positive (7 items), negative (7 items), and

        general psychopathology (16 items) subscale scores were summarized to

        give the PANSS total score.(3)

About a poster presentation entitled: Efficacy of Once-Daily Extended Release

Quetiapine Fumarate in Patients with Acute Schizophrenia

This first analysis of Study 132 evaluated the efficacy of SEROQUEL XR versus placebo in patients with schizophrenia. The primary endpoint was the change from baseline to Day 42 in PANSS total score.(1)

After six weeks, the mean PANSS total score decreased significantly with SEROQUEL XR (400 mg: -24.8, p < 0.05; 600 mg: -30.9, p < 0.001; 800 mg: -31.3, p < 0.001) compared with placebo (-18.8). In addition, PANSS response rates for SEROQUEL XR (all doses) were significantly higher than for placebo (p < 0.05).(1)

About a poster presentation entitled: Efficacy of Once-Daily Extended Release

Quetiapine Fumarate across Symptom Domains in Schizophrenia

In this second analysis of Study 132, the efficacy of SEROQUEL XR was evaluated across a broad range of symptoms in schizophrenia, including positive and negative symptoms as well as symptoms of general psychopathology, aggr
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/29/2014)... -- According to the new research ... Reagent, Primer, Probe, Custom Oligos), End-User (Research, Pharmaceutical ... NGS, DNA, RNAi) - Global Forecast to 2019" ... is expected to reach $1,712.1 Million by 2019 ... CAGR of 9.8% from 2014 to 2019.. ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... "Global Multiple Sclerosis Drugs Market 2014-2018" report to ... chronic, inflammatory medical condition that results in demyelination, axonal ... of an abnormal response by the immune system, which ... is a potentially debilitating disease in which the damage ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PR ... ("DelMar" "the Company") today announced the filing of June ... changed its fiscal year end to June 30th in ... stock on a national securities exchange in the timeliest ... with the United States Securities Exchange Commission can be ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... and FARGO, N.D., Dec. 16, 2011  Crystal3 Labs, Inc., a ... FL, announced today that it has been acquired by ... Financial terms of the transaction were not disclosed. The ... Pharma Analytics. Founded in 2007, Global Pharma ...
... 2011 Ekahau Inc. the leading global provider ... and KARL STORZ GmbH & Co. KG, the endoscopy specialist, ... Clinic in Berlin has successfully deployed and is using the ... and Ekahau RTLS for automatic real-time management of ...
Cached Medicine Technology:Crystal3 Labs Acquired by Individual Investor, Vithalbhai Dhaduk, M.D. 2Hospital Operating Rooms are now Optimized in Real-time With a Joint Solution From Karl Storz and Ekahau 2Hospital Operating Rooms are now Optimized in Real-time With a Joint Solution From Karl Storz and Ekahau 3Hospital Operating Rooms are now Optimized in Real-time With a Joint Solution From Karl Storz and Ekahau 4
(Date:8/30/2014)... United Theological Seminary is pleased to announce the launch of ... Studies (MTS). , This degree, which can ... wish to pursue further academic study of religion (Ph.D.) or ... and community. Previously, students needed to be on campus to ... any location where there is an internet connection. , ...
(Date:8/30/2014)... Denver, Colorado (PRWEB) August 30, 2014 Daily ... Cure for Yeast Infection is a method created by Sarah ... means. , The author of this new program actually ... created for any sufferer to be able to access it, ... had an important determination in finding an effective cure for ...
(Date:8/30/2014)... NY (PRWEB) August 30, 2014 ... throughout the planet has been one of the ... order to create a positive impact around the ... and staffed with top trained executives and trainers ... of people worldwide. Vital statistics demonstrate that ...
(Date:8/30/2014)... York (PRWEB) August 30, 2014 Hundreds ... mimetic claims continue to move forward in U.S. courts, ... by AstraZeneca PLC on July 31, 2014, Byetta and ... in 409 product liability claims that allege the drugs ... indicate that many of these claims are pending in ...
(Date:8/30/2014)... 30, 2014 Hastings and Hastings, a ... located throughout Arizona is pleased to report having saved ... specific example among many cases where Hastings and Hastings ... to retain a greater portion of their settlement or ... providing a positive solution for Arizona car accident victims ...
Breaking Medicine News(10 mins):Health News:United Theological Seminary Announces First Fully Online Degree 2Health News:Natural Cure for Yeast Infection Review Exposes New Natural Treatment 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2
... /PRNewswire/ - VisualSonics Inc., a leader in real time, ... the Board of Directors has permanently appointed Anil Amlani, ... Mr. Amlani, previously the Chief Financial Officer, has served ... 2009. , "VisualSonics has aggressive growth plans to expand ...
... , PHOENIX, Nov. 3 A healthy 44-year-old woman will ... Keri Sweeten and a new blood test for breast cancer. ... American College of Obstetricians and Gynecologists, recently incorporated the Provista ... of breast cancer, into her patient care practice. Sweeten noted ...
... ... best , ... November 3, 2009 -- Following approval by their Boards of Trustees, South Dakota-based Sanford ... two organizations have merged to become one of the country,s largest integrated health care systems. ...
... ... programs. , ... (PRWEB) November 3, 2009 -- Greenbrier Academy is a private young women,s ... transformative therapeutics. The school embraces virtuous relationships, personal excellence, and emotional breakthroughs inspiring ...
... ... the world,s first portable meeting cost calculator and clock. With Bring TIM!, time management is ... , ... November 3, 2009 -- Bring TIM! LLC announces the launch of Bring TIM!®, its new ...
... tubs, whirlpools and spas are widely used for relaxation and ... past two decades, as recreational use of hot tubs has ... conducted by the Center for Injury Research and Policy of ... 1990-2007, the number of unintentional hot tub-related injuries increased by ...
Cached Medicine News:Health News:VisualSonics Appoints New President and CEO 2Health News:A Breast Cancer Test That Saves Lives 2Health News:A Breast Cancer Test That Saves Lives 3Health News:Sanford and MeritCare Create a New Health System 2Health News:Sanford and MeritCare Create a New Health System 3Health News:Sanford and MeritCare Create a New Health System 4Health News:Therapeutic Boarding School to Provide Services Nationally 2Health News:Need a New Time Management Tool for Long Business Meetings? Bring TIM! 2Health News:New national study finds increasing number of injuries from hot tubs 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: